A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617

NCT07450157 | Completed

• 1 other identifier: CAAA617A1US19
• Study Type: observational
• Target: 6,448
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study was to evaluate patient characteristics, treatment patterns, prostate-specific antigen (PSA) reduction, and overall survival (OS) of prostate cancer patients treated with 177-Lutetium-Prostate-Specific Membrane Antigen-617 (177Lu-PSMA-617). Patient data from multiple electronic health record databases, including claims (open-source medical and pharmacy claims), consumer attributes, mortality, and laboratory data linked to claims databases was used. The study analysis was conducted in two phases. Phase I provided an early view of patients treated with 177Lu-PSMA-617 shortly after launch. Phase II refreshed the data, added mortality and extracted additional years of historical data to allow for the identification of the initial metastatic castrate-resistant prostate cancer (mCRPC) diagnosis and follow-up from that date through the start of 177Lu-PSMA-617.

Conditions

Prostate Cancer

Keywords

Metastatic castrate-resistant prostate cancer; Treatment patterns; Treatment response; Overall survival

Outcome Measures

Primary Outcomes (7)

• Number of Patients by Demographic Category

  Demographics included: * Age group * Geographical region * Payer type * Physician specialty * Race/ethnicity * Education level * Occupation

  Baseline

• Number of Patients by Clinical Characteristic Category

  Clinical characteristics included: * National Cancer Institute (NCI) comorbidity index * NCI category * Comorbidities * Metastasis sites * Number of distinct metastatic sites * PSA level category (≤ 4 ng/ml, \> 4 ng/ml)

  Baseline

• Clinical Characteristic: Baseline PSA Level

  Baseline

• Overall Survival (OS)

  OS was defined as the time from mCRPC diagnosis until death.

  Up to approximately 10 years

• Number of Patients who Died Within 6, 12, 24, and 36 Months From the mCRPC Diagnosis Date

  6, 12, 24, and 36 months

• Survival Time After the Last Administration of 177Lu-PSMA-617

  Up to approximately 10 years

• Number of Patients who Died After the Last Administration of 177Lu-PSMA-617

  Up to approximately 10 years

Secondary Outcomes (10)

• Percentage of Patients by Treatments Received From mCRPC Diagnosis to Initiation of 177Lu-PSMA-617

  Up to approximately 10 years

• Percentage of Patients by Line of 177Lu-PSMA-617 Initiation

  Up to approximately 10 years

• Percentage of Patients by Sequence of Treatments Prior to 177Lu-PSMA-617 Treatment

  Baseline

• Duration of Each Line of Treatment (LOT) by Treatment Received

  Up to approximately 10 years

• Time From mCRPC Diagnosis to Initiation of 177Lu-PSMA-617

  Up to approximately 10 years

Study Arms (4)

177Lu-PSMA-617 Patients Meeting Minimum Study Criteria

Phase I analysis group. Adult patients treated with 177Lu-PSMA-617 who met the minimum study criteria.

177Lu-PSMA-617 Patients with Pre- and Post-PSA Data Available

Phase I analysis group. Adult patients who met the minimum study criteria and had at least one PSA result available 28 days or more after the index date (177Lu-PSMA-617 initiation) while still on 177Lu-PSMA-617 treatment.

Patients who Received 177Lu-PSMA-617 at Anytime During the Study Period

Phase II analysis group. Adult patients with mCRPC who initiated 177Lu-PSMA-617 between 01 July 2014 and 30 September 2024 (index period).

Post-mCRPC 177Lu-PSMA-617 (≥6 Months Continuous Enrollment)

Phase II analysis group. Adult patients with continuous enrollment (CE) between the mCRPC diagnosis date and initiating 177Lu-PSMA-617 (index date), and at least 6 months of CE prior to the index date.

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with electronic health care records in multiple databases who were treated with 177Lu-PSMA-617.

You may qualify if:

• Patients with ≥1 claim in the open-source medical claims data with a Healthcare Common Procedure Coding System (HCPCS) code of A9607 or ≥1 claim in the open-source medical or pharmacy claims data with a National Drug Code (NDC) code for 177Lu-PSMA-617 during the patient selection window. The date of the first such claim is the index date.
• For patients identified via NDC code, ≥1 claim with one of the following procedure codes on the same date as the 177Lu-PSMA-617 NDC claim: HCPCS - A9699, J3590; CPT 79191; or ≥1 claim with HCPCS code A9595 or A9597 occurring within 14 days before or after the index date.
• At least 18 years of age at index date.
• Patients with ≥2 medical claims ≥180 days prior to the index date.
• For the treatment response analysis, the following additional criteria were applied:
• Patients with linkage to lab data.
• Patients with ≥1 PSA result available on or within 6 months prior to the index date. The PSA result closest to the index date was defined as the baseline PSA level.
• Patients with ≥1 PSA result available after the index date.
• ≥2 medical claims (≥30 days apart) with a diagnosis of prostate cancer observed during the patient selection period.
• ≥1 medical claim with a diagnosis code for metastatic disease occurring on or after the first observed prostate cancer diagnosis. The date of the first such claim was defined as the date of metastasis.
• Evidence of castration resistance observed during the study period. The date of mCRPC diagnosis was defined as the latest of the date of metastasis and the date of castration resistance and must have occurred during the index window.
• ≥12 months of continuous data availability prior to the mCRPC diagnosis date.
• ≥1 claim for 177Lu-PSMA-617 after mCRPC diagnosis and continuous data availability between diagnosis and the date of 177Lu-PSMA-617 initiation.

You may not qualify if:

• \. Standard data cleaning processes were applied to remove patients with data quality issues. Specific data quality issues included missing or invalid age or sex.

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

Study Sites (1)

Novartis

East Hanover, New Jersey, 07936, United States

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Novartis Pharmaceuticals

  Novartis Pharmaceuticals

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 27, 2026
• First Posted: March 4, 2026
• Study Start: June 23, 2023
• Primary Completion: February 28, 2025
• Study Completion: February 28, 2025
• Last Updated: March 4, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)